tofacitinib for UC
Selected indexed studies
- Ulcerative Colitis in Adults: A Review. (JAMA, 2023) [PMID:37698559]
- AGA Living Clinical Practice Guideline on Pharmacological Management of Moderate-to-Severe Ulcerative Colitis. (Gastroenterology, 2024) [PMID:39572132]
- Modern Advanced Therapies for Inflammatory Bowel Diseases: Practical Considerations and Positioning. (Clin Gastroenterol Hepatol, 2025) [PMID:39147217]
_Worker-drafted node — pending editorial review._
Connections
No connections recorded yet.
Sources
- AGA Living Clinical Practice Guideline on Pharmacological Management of Moderate-to-Severe Ulcerative Colitis. (2024) pubmed
- Modern Advanced Therapies for Inflammatory Bowel Diseases: Practical Considerations and Positioning. (2025) pubmed
- Cost-Effectiveness Analysis of Tofacitinib Compared with Biologics in Biologic-Naïve Patients with Moderate-to-Severe Ulcerative Colitis in Japan. (2023) pubmed
- British Society of Gastroenterology consensus guidelines on the management of inflammatory bowel disease in adults. (2019) pubmed
- Comparative Efficacy of Advanced Therapies for Management of Moderate-to-Severe Ulcerative Colitis: 2024 American Gastroenterological Association Evidence Synthesis. (2024) pubmed
- Ulcerative Colitis in Adults: A Review. (2023) pubmed
- PMID:34288615 (2019) pubmed
- Real-life effectiveness and safety of tofacitinib and vedolizumab as 2nd-line for ulcerative colitis after anti-TNFs: A multicenter cohort IGIBD study (VE2TO-UC). (2025) pubmed
- Review article: Updated management of acute severe ulcerative colitis: From steroids to novel medical strategies. (2023) pubmed
- Upadacitinib Is Effective and Safe in Both Ulcerative Colitis and Crohn's Disease: Prospective Real-World Experience. (2023) pubmed